Exact Mass: 408.0924
Exact Mass Matches: 408.0924
Found 54 metabolites which its exact mass value is equals to given mass value 408.0924,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Ethyl biscoumacetate
Ethyl 2,2-bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetic acid
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AA - Vitamin k antagonists D006401 - Hematologic Agents > D000925 - Anticoagulants > D015110 - 4-Hydroxycoumarins C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent
3,5,7,4-Tetrahydroxy-3-(5-formyl-2-hydroxyphenyl)flavanone
3,5,7,4-Tetrahydroxy-3- (5"-formyl-2"-hydroxyphenyl) flavanone
Torosaflavone C
(5bR,8aS)-rel-4H,5b,8a-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-6-methyl-8H-cyclopenta[4,5]furo[3,2-g]-1-benzopyran-4,8-dione
3,5,7-Trihydroxy-2,3-dihydro-2-(2,2-dihydroxy-5-formyl[1,1-biphenyl]-5-yl)-4H-1-benzopyran-4-one
3,5,7-Trihydroxy-2,3-dihydro-2-(2,2-dihydroxy-5-formyl[1,1-biphenyl]-5-yl)-4H-1-benzopyran-4-one
9-[(2,3-Dihydro-6-hydroxy-2-(hydroxymethyl)-3-benzofuranyl)oxy]3,10-dihydroxy-6H-dibenzo[b,d]pyran-6-one
9-[(2,3-Dihydro-6-hydroxy-2-(hydroxymethyl)-3-benzofuranyl)oxy]3,10-dihydroxy-6H-dibenzo[b,d]pyran-6-one
3-chloro-9beta,15-dihydroxy-8beta-tiglinoyloxy-dehydrleucodin
3-chloro-9beta,15-dihydroxy-8beta-tiglinoyloxy-dehydrleucodin
Cys Asp Asp Gly
(3S)-3-[(2R)-2-amino-3-sulfanylpropanamido]-3-{[(1S)-2-carboxy-1-[(carboxymethyl)carbamoyl]ethyl]carbamoyl}propanoic acid
Cys Asp Gly Asp
(2S)-2-{2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-carboxypropanamido]acetamido}butanedioic acid
Cys Gly Asp Asp
(2S)-2-[(2S)-2-{2-[(2R)-2-amino-3-sulfanylpropanamido]acetamido}-3-carboxypropanamido]butanedioic acid
Asp Cys Asp Gly
(3S)-3-[(2R)-2-[(2S)-2-amino-3-carboxypropanamido]-3-sulfanylpropanamido]-3-[(carboxymethyl)carbamoyl]propanoic acid
Asp Cys Gly Asp
(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-carboxypropanamido]-3-sulfanylpropanamido]acetamido}butanedioic acid
Asp Asp Cys Gly
(3S)-3-[(2S)-2-amino-3-carboxypropanamido]-3-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-sulfanylethyl]carbamoyl}propanoic acid
Asp Asp Gly Cys
(3S)-3-[(2S)-2-amino-3-carboxypropanamido]-3-[({[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}methyl)carbamoyl]propanoic acid
Asp Gly Cys Asp
(2S)-2-[(2R)-2-{2-[(2S)-2-amino-3-carboxypropanamido]acetamido}-3-sulfanylpropanamido]butanedioic acid
Asp Gly Asp Cys
(3S)-3-{2-[(2S)-2-amino-3-carboxypropanamido]acetamido}-3-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}propanoic acid
Gly Cys Asp Asp
(2S)-2-[(2S)-2-[(2R)-2-(2-aminoacetamido)-3-sulfanylpropanamido]-3-carboxypropanamido]butanedioic acid
Gly Asp Cys Asp
(2S)-2-[(2R)-2-[(2S)-2-(2-aminoacetamido)-3-carboxypropanamido]-3-sulfanylpropanamido]butanedioic acid
Gly Asp Asp Cys
(3S)-3-[(2S)-2-(2-aminoacetamido)-3-carboxypropanamido]-3-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}propanoic acid
4-[4,5-DIHYDRO-5-(1H-INDOL-3-YL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]-BENZENESULFONAMIDE
4-[4,5-DIHYDRO-5-(1H-INDOL-3-YL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]-BENZENESULFONAMIDE
2,6-dimethoxy-4-methyl-8-nitro-5-[3-(trifluoromethyl)phenoxy]quinoline
2,6-dimethoxy-4-methyl-8-nitro-5-[3-(trifluoromethyl)phenoxy]quinoline
2-BENZAMIDO-3-(4-(N,N-BIS-(2-CHLOROETHYL)AMINO)PHENYL)PROPIONIC ACID
2-BENZAMIDO-3-(4-(N,N-BIS-(2-CHLOROETHYL)AMINO)PHENYL)PROPIONIC ACID
3,9-dibenzyl-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane 3,9-dioxide
3,9-dibenzyl-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane 3,9-dioxide
Leriglitazone hydrochloride
Leriglitazone hydrochloride
C78272 - Agent Affecting Nervous System Leriglitazone (MIN-102; Hydroxypioglitazone) hydrochloride, a metabolite of pioglitazone. Leriglitazone hydrochloride PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone hydrochloride binds to the PPARγ C-terminal ligand-binding domain (LBD) with a Ki of 1.2 μM，Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC50 of 680 nM[1].
(1R)-N,6-Dihydroxy-7-methoxy-2-[(4-methoxyphenyl)sulfonyl]-1,2,3,4-tetrahydroisoquinoline-1-carboxamide
(1R)-N,6-Dihydroxy-7-methoxy-2-[(4-methoxyphenyl)sulfonyl]-1,2,3,4-tetrahydroisoquinoline-1-carboxamide
Ethyl Biscoumacetate
Ethyl Biscoumacetate
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AA - Vitamin k antagonists D006401 - Hematologic Agents > D000925 - Anticoagulants > D015110 - 4-Hydroxycoumarins C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent
N-[2-[[1-(4-methylphenyl)-4-pyrazolo[3,4-d]pyrimidinyl]thio]-1-oxoethyl]-2-furancarbohydrazide
N-[2-[[1-(4-methylphenyl)-4-pyrazolo[3,4-d]pyrimidinyl]thio]-1-oxoethyl]-2-furancarbohydrazide
3-(4-chlorophenyl)-4-[(E)-(3,5-dimethyl-1-phenylpyrazol-4-yl)methylideneamino]-1H-1,2,4-triazole-5-thione
3-(4-chlorophenyl)-4-[(E)-(3,5-dimethyl-1-phenylpyrazol-4-yl)methylideneamino]-1H-1,2,4-triazole-5-thione
2-(4-Bromophenyl)-2-oxoethyl 12-oxododec-9(Z)-enoate
2-(4-Bromophenyl)-2-oxoethyl 12-oxododec-9(Z)-enoate
(4s,8s,10s)-16-acetyl-2,12-dihydroxy-10-methyl-5,9-dioxapentacyclo[11.8.0.0³,¹¹.0⁴,⁸.0¹⁵,²⁰]henicosa-1,3(11),12,15(20),16,18-hexaene-6,14,21-trione
(4s,8s,10s)-16-acetyl-2,12-dihydroxy-10-methyl-5,9-dioxapentacyclo[11.8.0.0³,¹¹.0⁴,⁸.0¹⁵,²⁰]henicosa-1,3(11),12,15(20),16,18-hexaene-6,14,21-trione
(3as,4s,5r,9ar,9br)-8-chloro-5-hydroxy-9-(hydroxymethyl)-6-methyl-3-methylidene-2,7-dioxo-3ah,4h,5h,9ah,9bh-azuleno[4,5-b]furan-4-yl (2e)-2-methylbut-2-enoate
(3as,4s,5r,9ar,9br)-8-chloro-5-hydroxy-9-(hydroxymethyl)-6-methyl-3-methylidene-2,7-dioxo-3ah,4h,5h,9ah,9bh-azuleno[4,5-b]furan-4-yl (2e)-2-methylbut-2-enoate
methyl 2-ethyl-6,7,10,11-tetrahydroxy-5,12-dioxotetracene-1-carboxylate
methyl 2-ethyl-6,7,10,11-tetrahydroxy-5,12-dioxotetracene-1-carboxylate
2-[1,2-dihydroxy-1-(oxiran-2-yl)ethyl]-11-hydroxy-5-methyl-1-oxatetraphene-4,7,12-trione
2-[1,2-dihydroxy-1-(oxiran-2-yl)ethyl]-11-hydroxy-5-methyl-1-oxatetraphene-4,7,12-trione
methyl 2-ethyl-4,5,7,12-tetrahydroxy-6,11-dioxotetracene-1-carboxylate
methyl 2-ethyl-4,5,7,12-tetrahydroxy-6,11-dioxotetracene-1-carboxylate
16-acetyl-2,12-dihydroxy-10-methyl-5,9-dioxapentacyclo[11.8.0.0³,¹¹.0⁴,⁸.0¹⁵,²⁰]henicosa-1,3(11),12,15(20),16,18-hexaene-6,14,21-trione
16-acetyl-2,12-dihydroxy-10-methyl-5,9-dioxapentacyclo[11.8.0.0³,¹¹.0⁴,⁸.0¹⁵,²⁰]henicosa-1,3(11),12,15(20),16,18-hexaene-6,14,21-trione
2',6-dihydroxy-5'-[(2s,3r)-3,5,7-trihydroxy-4-oxo-2,3-dihydro-1-benzopyran-2-yl]-[1,1'-biphenyl]-3-carbaldehyde
2',6-dihydroxy-5'-[(2s,3r)-3,5,7-trihydroxy-4-oxo-2,3-dihydro-1-benzopyran-2-yl]-[1,1'-biphenyl]-3-carbaldehyde
2-{2,4-dihydroxy-6-[(4-hydroxy-6-oxopyran-2-yl)methyl]phenyl}-7-hydroxy-5-methylchromen-4-one
2-{2,4-dihydroxy-6-[(4-hydroxy-6-oxopyran-2-yl)methyl]phenyl}-7-hydroxy-5-methylchromen-4-one
2',6-dihydroxy-5'-(3,5,7-trihydroxy-4-oxo-2,3-dihydro-1-benzopyran-2-yl)-[1,1'-biphenyl]-3-carbaldehyde
2',6-dihydroxy-5'-(3,5,7-trihydroxy-4-oxo-2,3-dihydro-1-benzopyran-2-yl)-[1,1'-biphenyl]-3-carbaldehyde
8-chloro-5-hydroxy-9-(hydroxymethyl)-6-methyl-3-methylidene-2,7-dioxo-3ah,4h,5h,9ah,9bh-azuleno[4,5-b]furan-4-yl 2-methylbut-2-enoate
8-chloro-5-hydroxy-9-(hydroxymethyl)-6-methyl-3-methylidene-2,7-dioxo-3ah,4h,5h,9ah,9bh-azuleno[4,5-b]furan-4-yl 2-methylbut-2-enoate
2-hydroxy-3-(4-hydroxyphenyl)-4,7-diphenyl-1-benzofuran-5,6-dione
2-hydroxy-3-(4-hydroxyphenyl)-4,7-diphenyl-1-benzofuran-5,6-dione
